

Board of Governors Meeting via Teleconference / Webinar

Tuesday, August 20, 2019

12:00 pm - 1:30 pm ET

MINUTES

Board Members Present:

Christine Goertz, DC, PhD; *Vice Chairperson*; Kara Ayers, PhD; Larry Becker; Francis S. Collins, MD, PhD; Jennifer DeVoe, MD, DPhil; Trent Haywood, MD, JD; Michael Herndon, DO; Russell Howerton, MD; Gail Hunt; David Meyers, MD (designee for Gopal Khanna, MBA); Sharon Levine, MD; Freda Lewis-Hall, MD; Michelle McMurry-Heath, MD, PhD; Ellen Sigal, PhD; Janet Woodcock, MD; Robert Zwolak, MD, PhD

Board Members Absent:

Grayson Norquist, MD, MSPH, *Chairperson*; Alicia Fernandez, MD; Christopher Frieze, PhD, RN; Barbara McNeil, MD, PhD; Kathleen Troeger, MPH

Agenda Item	PCORI Speakers
Call to Order, Roll Call, and Welcome - Christine Goertz, DC, PhD, <i>Vice Chairperson</i>, and Joe Selby, MD, MPH, <i>Executive Director</i>	Dr. Goertz chaired and opened the meeting, welcomed all to the meeting of the PCORI Board of Governors and read the Chair Statement on Conflict of Interest. Dr. Joe Selby then reviewed the meeting agenda.
Consider for Approval: Minutes of the July 23, 2019 Board Meeting - Christine Goertz, DC, PhD	<i>The following motion was made by Ellen Sigal and seconded by Russell Howerton.</i> Motion: Approve the Minutes of the July 23, 2019 Board Meeting. <i>Approved by a majority vote of the voting Board members (no opposed; no abstentions).</i>
Consider for Approval: Approve New Advisory Panelists, Chairs, and Co-Chairs • Rare Disease • Clinical Trials • Clinical Effectiveness and Decision Science • Healthcare Delivery and Disparities Research • Patient Engagement - Robert Zwolak, MD, <i>Chair, Science Oversight Committee</i>, and Joe Selby, MD, MPH, <i>Executive Director</i> - Sharon Levine, MD, <i>Chair, Engagement, Dissemination and Implementation Committee</i>, and Kristin Carman,	Dr. Zwolak noted that the Science Oversight Committee (SOC) was pleased to review the proposed panelists for the Rare Disease Advisory Panel (RDAP), the Clinical Trials Advisory Panel (CTAP), the Clinical Effectiveness and Decision Science Advisory Panel (CEDS AP), and the Healthcare Delivery and Disparities Research Advisory Panel (HDDR AP). He stated that these panelists have the full recommendation of the SOC for approval by the Board. He also noted that the Methodology Committee reviewed the proposed panelists for the Clinical Trials Advisory Panel (CTAP) and is pleased to recommend these panelists for Board approval. Dr. Selby thanked the staff for their efforts in making sure the panels represent multiple dimensions of diversity and noted the exceptional and numerous applications that were received for a limited number of open slots. Dr. Carman then provided an overview of the Advisory Panel review process, which included the review timeline, the number of applications received per panel, and the maximum number of available openings on each panel. She noted that of the 215

<i>MA, PhD, Director, Public and Patient Engagement</i>	applications received, 23 panelists were being put forth for Board approval. Selby then presented the proposed slates of new Advisory Panel members, their bios, positions, and terms for the Rare Disease Advisory Panel (RDAP), the Clinical Trials Advisory Panel (CTAP), the Clinical Effectiveness and Decision Science Advisory Panel (CEDS AP), and the Healthcare Delivery and Disparities Research Advisory Panel (HDDR AP). (See Attachment A) Dr. Levine then introduced Carman to present the proposed slate of proposed new Advisory Panel members, their positions and terms, who had been approved by the Engagement, Dissemination, and Implementation Committee (EDIC) to be recommended to the Board for service on the Patient Engagement Advisory Panel (PEAP). (See Attachment A) <i>The following motion was made by Sharon Levine and seconded by Gail Hunt.</i> Motion: Approve the proposed slates of members, positions and terms for the following Advisory Panels: RDAP, CTAP, CEDS AP, HDDR AP and PEAP. <i>Approved by a majority vote of the voting Board members (no opposed; one abstention: Janet Woodcock). Michelle McMurry-Health was not present for this vote.</i>
Consider for Approval: Proposed Cycle3 2018 Slate of Awards Broad PFA	Dr. Selby made introductory remarks on behalf of the Selection Committee and then proceeded to introduce the proposed slate for the Cycle 3 2018 Broad PFAs Award Slate. He provided a brief overview of the process and budget for the Cycle 3 2018 Broad PFAs. Of the 189 Letters of Intent submitted, 100 (53%) were invited to submit a full application. Of these, 73 applications were received. On July 22, 2019, the Selection Committee recommended to fund a slate of eleven applications (15%) for a proposed total commitment of \$29.3M out of the posted \$76M. Selby noted that all proposed projects, including requested budgets and project periods, are approved subject to a programmatic and budget review by PCORI staff and the negotiation of a formal award contract. The Broad slate consists of 11 research projects from different priority areas (<i>See Attachment B</i>): Addressing Disparities (1 recommended project); Assessment of Prevention, Diagnosis, and Treatment Options (3 recommended projects); Communication and Dissemination research (1 recommended project); Improving Healthcare Systems (2 recommended projects); and Improving Methods for Conducting PCOR (4 recommended projects).



	<i>(See Attachment B for the list of Cycle 3 2018 Broad PFA projects funded.)</i> <i>The following motion was made by Larry Becker and seconded by Gail Hunt:</i> Motion: Approve funding for the recommended slate of awards from the Cycle 3 2018 Broad PFAs. <i>Approved by a majority vote of the voting Board members by roll call vote (13 in favor; 0 opposed; 3 recusals: Kara Ayers, Janet Woodcock, Robert Zwolak)</i>
Wrap up and Adjournment - Christine Goertz, DC, PhD	Meeting ended at 12:58 pm.

See attachments A and B below

Minutes were approved by the PCORI Board of Governors 09-18-2019

ATTACHMENT A: Advisory Panel Members, Chairs and Co-Chairs, Terms

Advisory Panel on Rare Disease:

Name	Stakeholder Group	Primary Affiliation	Term length (or until replacements are appointed)
Saira Sultan*	Policy Makers	The Haystack Project	3 years
Doug Lindsay	Patients, Caregivers and Patient Advocates	Doug Says, LLC	3 years

Advisory Panel on Clinical Trials:

Name	Stakeholder Group	Primary Affiliation	Term length (or until replacements are appointed)
Yuelin Li	Researchers	Memorial Sloan Kettering Cancer Center	3 years
Jacqueline Corrigan-Curay	Policy Makers	FDA	3 years
Wenora Johnson	Patients, Caregivers and Patient Advocates	Argonne National Laboratory	3 years
Maryam Tabatabai*	Payers	Magellan Health, Inc.	3 years

Advisory Panel on Clinical Trials: Proposed Chair

Name	Stakeholder Group	Primary Affiliation	Term length (or until replacements are appointed)
Andrea Troxel	Researchers	New York University School of Medicine	1 year

Advisory Panel on Clinical Effectiveness and Decision Science:

Name	Stakeholder Group	Primary Affiliation	Term length (or until replacements are appointed)
------	-------------------	---------------------	---

Eric Cannon*	Payers	SelectHealth	3 years
David Webster	Payers	Highmark	3 years

Advisory Panel on Healthcare Delivery & Disparities Research:

Name	Stakeholder Group	Primary Affiliation	Term length (or until replacements are appointed)
Alicia Arbaje	Researchers	Johns Hopkins University	3 years
Ana Lopez	Patients, Caregivers and Patient Advocates	The University of Texas MD Anderson Cancer Center	3 years
Jane Kogan*	Payers	UPMC Center for High-Value Health	3 years
Jennifer Potter*	Clinicians	Beth Israel Deaconess Medical Center/Harvard Medical School	3 years
Kathleen Kieran	Clinicians	Seattle Children's Hospital	3 years
Marissa Sanders	Payers	American Dental Assn	3 years
Rainu Kaushal	Researchers	Weill Cornell Medicine	3 years
Thomas James*	Payers	Highmark, Inc.	3 years
Xiaoduo Fan*	Hospitals/Health Systems	University of Massachusetts Medical School	3 years

Advisory Panel on Healthcare Delivery & Disparities Research: Co-Chairs

Name	Stakeholder Group	Primary Affiliation	Term length (or until replacements are appointed)
James Frank Wharam	Researchers	Harvard Pilgrim Health Care Institute	1 year
Nadine Barrett	Hospitals/Health Systems	Duke Cancer Institute	1 year

Advisory Panel on Patient Engagement:

Name	Stakeholder Group	Primary Affiliation	Term length (or until replacements are appointed)
------	-------------------	---------------------	---

			appointed)
Beth Careyva	Researchers	Lehigh Valley Hospital, Inc.	3 years
Tracy Carney*	Patients, Caregivers and Patient Advocates	Community Care Behavioral Health	3 years
Crispin Goytia	Patients, Caregivers and Patient Advocates	Icahn School of Medicine at Mount Sinai	3 years
Danny van Leeuwen	Patients, Caregivers and Patient Advocates	Health Hats	3 years
Simon Mathews	Clinicians	Johns Hopkins University Armstrong Institute for Patient Safety and Quality	3 years
Neely Williams	Patients, Caregivers and Patient Advocates	Community Partners' Network, Inc.	3 years

Advisory Panel on Patient Engagement: Proposed Chair and Co-Chair

Name	Stakeholder Group	Primary Affiliation	Term length (or until replacements are appointed)
New Chair			
Thomas Scheid	Patients, Caregivers and Patient Advocates	Retired	1 year
New Co-Chair			
Gwen Darien	Patients, Caregivers and Patient Advocates	National Patient Advocate Foundation	2 years

*Proposed panelists that were nominated by a third-party organization have been marked with an asterisk.

ATTACHMENT B: Slate Approved of Cycle 3 2018 Broad PFA Awards

Program	Awarded Project
Addressing Disparities	Comparative Effectiveness of Multi vs. Single Intervention Allergen Reduction Strategies on Asthma Morbidity
Assessment of Prevention, Diagnosis, and Treatment Options	Comparative Effectiveness of Pediatric Kidney Stone Surgery
	Comparative Effectiveness of Family Diabetes Self-Management Education (DSME) and Standard-DSME among Diverse Populations
	Comparative Effectiveness of Cognitive Enhancement Therapy vs. Social Skills Training in Serious Mental Illness (SMI)
Communication and Dissemination	Measuring the Impact of Providing Personalized Risk Information to Patients and Their Providers
Improving Healthcare Systems	Comparing Safety Planning + Follow-Up vs. Safety Planning Alone for Suicide Prevention in Emergency Departments (EDs) and Primary Care
	Innovative Care Model for Older Adults with Chronic Heart Failure (i-COACH): A Comparative Effectiveness Clinical Trial
Improving Methods for Conducting PCOR	A Two-Stage Meta-Regression Framework for Precision Medicine Using Data from Clinical Research
	Improving Natural Language Processing (NLP) Methods for Unstructured Clinical Data Reuse
	NLP to Connect Social Determinants and Clinical Factors for Outcomes Research
	Use of Public Deliberation in Diverse Communities to Improve Consent Processes for Clinical Research